期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
A network of conformational transitions in an unfolding process of HP-35 revealed by high-temperature MD simulation and a Markov state model
1
作者 邵丹丹 高恺夫 《Chinese Physics B》 SCIE EI CAS CSCD 2018年第1期175-181,共7页
An understanding of protein folding/unfolding processes has important implications for all biological processes, in- eluding protein degradation, protein translocation, aging, and diseases. All-atom molecular dynamics... An understanding of protein folding/unfolding processes has important implications for all biological processes, in- eluding protein degradation, protein translocation, aging, and diseases. All-atom molecular dynamics (MD) simulations are uniquely suitable for it because of their atomic level resolution and accuracy. However, limited by computational ca- pabilities, nowadays even for small and fast-folding proteins, all-atom MD simulations of protein folding still presents a great challenge. An alternative way is to study unfolding process using MD simulations at high temperature. High temper- ature provides more energy to overcome energetic barriers to unfolding, and information obtained from studying unfolding can shed light on the mechanism of folding. In the present study, a 1000-ns MD simulation at high temperature (500 K) was performed to investigate the unfolding process of a small protein, chicken villin headpiece (HP-35). To infer the folding mechanism, a Markov state model was also built from our simulation, which maps out six macrostates during the folding/unfolding process as well as critical transitions between them, revealing the folding mechanism unambiguously. 展开更多
关键词 molecular dynamics simulation Markov state model folding/unfolding hp-35
下载PDF
SUD-35/羟丙基-β-环糊精包合物的制备及其小鼠体内药效学初步研究
2
作者 潘振华 刘焕龙 +3 位作者 陈雪彦 向柏 方瑜 张永健 《中国药房》 CAS CSCD 北大核心 2011年第21期1982-1984,共3页
目的:制备苯甲酰脲类微管微丝抑制剂SUD-35/羟丙基-β-环糊精包合物(SUD-35/HP-β-CD),以提高SUD-35的水溶性和稳定性,并对其小鼠体内药效学进行初步考察。方法:采用饱和水溶液法,以SUD-35/HP-β-CD投药比(A)、包合温度(B)、包合时间(C... 目的:制备苯甲酰脲类微管微丝抑制剂SUD-35/羟丙基-β-环糊精包合物(SUD-35/HP-β-CD),以提高SUD-35的水溶性和稳定性,并对其小鼠体内药效学进行初步考察。方法:采用饱和水溶液法,以SUD-35/HP-β-CD投药比(A)、包合温度(B)、包合时间(C)、搅拌速度(D)为考察因素,以包合率为考察指标,设计正交试验筛选最佳制备工艺并进行验证试验和溶解度测定;以差示扫描量热(DSC)法及X射线衍射(XRD)法验证包合物;对肝癌H22细胞实体瘤模型小鼠腹腔注射包合物低、中、高剂量(以SUD-35计)每日1次,共7d,计算末次给药后24h的抑瘤率,并与环磷酰胺比较。结果:最佳制备工艺为A:1∶5,B:50℃,C:60min,D:100r·min-1;以此工艺所制3批包合物的平均包合率约为75.8%;SUD-35原料及其包合物在水中的溶解度分别为0.00032、0.65g·L-1;DSC和XRD法证实包合物形成;低、中、高剂量抑瘤率分别为(38.25±0.57)%、(63.45±1.20)%、(69.26±1.15)%,环磷酰胺组为(71.52±1.16)%。结论:SUD-35/HP-β-CD包合物的制备工艺简便、易行,可极大地提高SUD-35的水溶性,其高剂量对肝癌H22细胞在小鼠体内的生长具有与环磷酰胺相似的抑制作用。 展开更多
关键词 微管微丝抑制剂 SUD-35 羟丙基-Β-环糊精 包合物 正交试验 小鼠 肝癌H22细胞 抑瘤率
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部